Overview

Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%

Status:
Withdrawn
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
A multi-center, observer-masked, randomized, parallel group efficacy and safety study of TRAVATAN® versus a new formulation of Travoprost Ophthalmic Solution, 0.004%
Phase:
Phase 3
Details
Lead Sponsor:
Alcon Research
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions
Travoprost